Rise in patient reporting boosts EU drug safety signals
This article was originally published in SRA
The introduction of direct reporting of adverse drug reactions by patients in Europe appears to have had the desired effect: in 2013, the number of ADRs reported by patients within the European Economic Area rose by more than 50% as a result of greater public awareness of the importance of such reporting.
You may also be interested in...
Hydroxyethyl-starch solutions are being suspended from the EU following the failure of several safety measures that were introduced to prevent their use in certain high-risk patient groups.
A coordinated effort will be needed if Africa is to increase its manufacturing capacity and ensure a market for domestically produced vaccines.
Pharma firms in France are facing tougher sanctions from October if they fail to honor their obligations in terms of anticipating and managing potential or actual drug shortages.